O2 : Towards a living biobank of surgically-relevant 3-dimensional glioblastoma stem cell models to evaluate novel therapeutics and interrogate intratumoural heterogeneity

Rominiyi, Ola and Vanderlinden, A and Myers, K. and Gomez-Roman, Natividad and Dar, D. and Bagga, V. and Jellinek, D. A. and Chalmers, Anthony and Carroll, T. A. and Al-Tamimi, Y. and Collis, S. J. (2021) O2 : Towards a living biobank of surgically-relevant 3-dimensional glioblastoma stem cell models to evaluate novel therapeutics and interrogate intratumoural heterogeneity. British Journal of Surgery, 108 (Suppl ). znab117.002. ISSN 1365-2168 (https://doi.org/10.1093/bjs/znab117.002)

[thumbnail of Rominiyi-etal-BJS2021-O2-towards-living-biobank-surgically-relevant 3-dimensional-glioblastoma-stem-cell-models]
Preview
 Text. Filename: Rominiyi_etal_BJS2021_O2_towards_living_biobank_surgically_relevant_3_dimensional_glioblastoma_stem_cell_models.pdf
Final Published Version
License: Creative Commons Attribution-NonCommercial 4.0 logo
Download (79kB)| Preview

Abstract

Introduction: Glioblastoma is the most common cancer arising within the brain. Despite surgery, followed by DNA‐damaging chemoradiotherapy, average survival remains between 12‐15 months. Unacceptable survival rates underline the need to develop preclinical research models which recapitulate features underpinning therapeutic resistance in patients, such as intratumoural heterogeneity and treatment resistant glioblastoma stem cell (GSC) subpopulations which demonstrate elevated DNA damage response (DDR) activity. Method: Tumour specimens from patients were used to generate 2D and 3D scaffold‐based GSC models, with a range of preclinical survival and molecular assays used to interrogate cancer biology and assess therapeutic responses. Result: We have developed a ‘living biobank’ of 20+ ex‐vivo GSC models which reflect key clinicopathological diversity. These models include residual disease models based on careful macrodissection of rare en‐blocpartial lobectomy specimens to liberate parallel GSC lines from the tumour core and adjacent infiltrated brain, to represent cells typically left behind after surgery. Therapeutic strategies targeting fundamental DDR processes demonstrate preclinical efficacy, for example dual inhibition of ATR and the FA DNA damage repair pathways elicits profound radiosensitisation (sensitiser enhancement ratio of 3.23 (3.03‐3.49, 95%‐CI)) with evidence of delayed DNA damage repair on single‐cell gel electrophoresis. Finally, characterisation of our surgically‐relevant resected and residual models reveals numerous divergent properties including elevated stem cell marker expression in residual models (p=0.0021), which may partially explain treatment resistance in disease left behind after surgery. Conclusion: Our living biobank represents a useful resource for preclinical glioblastoma research and demonstrates the value of partnership between surgeons and laboratory‐based scientists. Take‐home message: Our living biobank represents a useful resource for preclinical glioblastoma research and demonstrates the value of partnership between surgeons and laboratory‐based scientists.

ORCID iDs

Rominiyi, Ola, Vanderlinden, A, Myers, K., Gomez-Roman, Natividad ORCID logoORCID: https://orcid.org/0000-0002-2325-7517, Dar, D., Bagga, V., Jellinek, D. A., Chalmers, Anthony, Carroll, T. A., Al-Tamimi, Y. and Collis, S. J.;
  • Item type:Article
    ID code:86196
    Dates:
    Date
    Event
    27 April 2021
    Published
    1 September 2020
    Accepted
    Notes:O Rominiyi and others, O2: TOWARDS A LIVING BIOBANK OF SURGICALLY‐RELEVANT 3‐DIMENSIONAL GLIOBLASTOMA STEM CELL MODELS TO EVALUATE NOVEL THERAPEUTICS AND INTERROGATE INTRATUMOURAL HETEROGENEITY, British Journal of Surgery, Volume 108, Issue Supplement_1, March 2021, znab117.002, https://doi.org/10.1093/bjs/znab117.002 © The Author(s) 2021. Published by Oxford University Press on behalf of BJS Society Ltd. All rights reserved. [br]For permissions, please email: journals.permissions@oup.com
    Subjects:Medicine > Internal medicine > Neoplasms. Tumors. Oncology (including Cancer)
    Department:Faculty of Science > Strathclyde Institute of Pharmacy and Biomedical Sciences
    Depositing user: Pure Administrator
    Date deposited:20 Jul 2023 10:54
    Last modified:11 Nov 2024 13:59
    URI:https://strathprints.strath.ac.uk/id/eprint/86196
CORE (COnnecting REpositories)